Released Aug 11, 2022, after the close
10-Q filed Aug 11, 2022, 42 days after period end · 0001140361-22-029251
Q2 2022 · 10-Q
Revenue—
Net Income-$3.40M-$3.40M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$1.16-$1.16 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$13,880,000N/M
Operating Cash Flowderived-$3,993,000N/M
Free Cash Flowderived-$4,180,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | — | — | $754.00K | $5.23M |
| Net Income | -$3.40M | -$10.09M | -$2.03M | -$90.00K |
| EPS Diluted | -$1.16 | -$0.24 | -$0.12 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR